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Abstract:Disconnections between in vitro responses and those
observed in whole cells confound many attempts to design
drugs in areas of serious medical need. A method based on 1D
1H NMR spectroscopy is reported that affords the ability to
monitor the hydrolytic decomposition of the carbapenem
antibiotic meropenem inside Escherichia coli cells expressing
New Delhi metallo-b-lactamase subclass 1 (NDM-1), an
emerging antibiotic-resistance threat. Cell-based NMR studies
demonstrated that two known NDM-1 inhibitors, l-captopril
and ethylenediaminetetraacetic acid (EDTA), inhibit the
hydrolysis of meropenem in vivo. NDM-1 activity in cells
was also shown to be inhibited by spermine, a porin inhibitor,
although in an in vitro assay, the influence of spermine on the
activity of isolated NDM-1 protein is minimal. This new
approach may have generic utility for monitoring reactions
involving diffusible metabolites in other complex biological
matrices and whole-cell settings, including mammalian cells.
Our knowledge of the structure and function of enzymes is
obtained primarily through in vitro studies performed with-
out the complete context of the physiological environment.
As the scope of our understanding of individual components
in cells becomes ever broader, we are motivated to explore
protein structure and function in living cells in spite of the
daunting challenges that arise from the complexity of the
dynamic cellular environment and biological network.[1]
NMR spectroscopy is known as a noninvasive method for
detecting substances. “In-cell” NMR technology, which aims
to detect signals of overexpressed or introduced 15N-labeled
proteins in living cells, has shown itself capable, in favorable
circumstances, of providing valuable information about
protein structure, folding, dynamics, and interaction with
other cellular components in the native or seminative cellular
environment.[2]
It has long been speculated that in-cell NMR could make
useful contributions to the drug discovery process,[3] partic-
ularly in the area of anti-infective research on serious
bacterial pathogens. An example is provided by STINT-
NMR, a technology based on the isotope labeling of only one
partner in an intracellular protein complex by sequential
expression.[4] This technology has been applied to the screen-
ing of a small-molecule interactor library for compounds that
can disrupt protein–protein interactions.[5] However, the
extent to which approaches based on the direct observation
of the NMR resonances of proteins within the cellular milieu
can be generally useful remains unclear. A number of factors
conspire to render the observation of high-resolution spectra
from intracellular globular proteins difficult: the elevated
viscosity of the cytoplasm, macromolecular crowding effects
that limit rotational and translational diffusion, and multiple
transient protein–protein interactions driven by electrostatic
interaction can all cause line broadening that can be so severe
as to render all but the most mobile resonances of even
relatively small proteins unobservable when these are over-
expressed or introduced into the intracellular compart-
ment.[6, 7] Furthermore, the requirement to overexpress the
protein(s) of interest substantially beyond their native
expression levels can significantly perturb cellular function,
thus calling into question the physiological relevance of the
system under investigation. By contrast, monitoring small
molecules such as drugs or metabolites after drug treatment in
living cells should be relatively straightforward and feasible.[8]
In this case, the big hurdles for in-cell NMR, such as protein
size limitation, isotope labeling, and overexpression, are
avoided.
Our leading weapons against bacterial infections are b-
lactams, which kill bacteria by inhibiting transpeptidases
during bacterial cell-wall biosynthesis.[9] One of the defense
mechanisms that bacteria have evolved is to produce a variety
of b-lactamases that disarm b-lactams by opening the cyclic
amide ring.[9,10] Gram-negative bacterial pathogens such as
Escherichia coli and Klebsiella pneumoniae that carry the
New Delhi Metallo-b-lactamase subclass 1 (NDM-1) are
called “superbugs” because they are resistant to most anti-
biotics and are challenging to treat.[11] NDM-1 is a Class B b-
lactamase.[9, 11]Unlike Class A, C, and D b-lactamases, Class B
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b-lactamases possess a unique catalytic mechanism that
utilizes Zn2+ ions in the ring opening of b-lactams.[12]
Carbapenems such as meropenem and imipenem, once
trusted as a last resort to treat the most serious bacterial
infections, can now be hydrolyzed by various b-lactamases, in
particular, NDM-1 (Scheme 1).[13] This reaction can be
observed by using an in vitro NMR assay in which merope-
nem is treated with the purified NDM-1 enzyme (Figure 1A).
Meropenem is relatively stable for a long period of time in E.
coli cells lacking carbapenemases (Figure 1B). However, the
drug is gradually degraded in the presence of E. coli cells
carrying the NDM-1 enzyme (Figure 1C). Despite the back-
ground signals from the cells and sample preparation (Fig-
ure S1 in the Supporting Information), the hydrolysis process
can be clearly monitored by focusing on the 1H NMR signals
from the methyl groups on meropenem. Under the exper-
imental conditions employed (100 mm meropenem and a sus-
pension of NDM-1 E. coli cells with an optical density at
600 nm (OD600) of 2.5 in sodium phosphate buffer), the
intensity of the 1H signals from the methyl groups is about
fivefold higher than from cells alone (Figure 1B and C). In
addition, the background 1H signals from the aromatic region
are negligible (Figure S2), thus making this method generally
applicable to common drugs and compounds in chemical
libraries, of which approximately 80% have aromatic
groups.[14] It is also a sensitive assay: even the terminal 
N(CH3)2 protons (
1H chemical shifts: d= 3.07 and 2.99 ppm,
Figure 1) yield resolvable changes in chemical shift on ring
opening. The viability of the NDM-1 E. coli cells was checked
before and after the NMR experiments. The plating colony
test shows that one hour of NMR measurements did not lead
to any change in cell viability (Figure S3). To confirm that the
enzymatic activity is from NDM-1 in the cells and to rule out
the possibility that meropenem induces cell lysis and subse-
quent NDM-1 leakage into the medium, NDM-1 E. coli cells
treated with meropenem were spun down and fresh merope-
nem was added to the supernatant to monitor the change in
the meropenem 1H signals. Hydrolysis of meropenem was not
observed (Figure S4), which demonstrates that the reaction
occurs inside the cells. By contrast, when periplasmic proteins
were released by treating NDM-1 E. coli cells with chloro-
form,[15] hydrolysis of meropenem in the supernatant was
observed by NMR spectroscopy (Figure S5). This result
strongly supports the conclusion that the enzymatic reaction
catalyzed by NDM-1 indeed occurs in the periplasmic space
where most b-lactamases are known to reside.[12]
The stability of a few selected antibiotics (Figure S6) that
display broad-spectrum antibacterial activities was compared
in the presence of NDM-1 E. coli cells (Figure 2). It is known
that NDM-1-positive strains are no longer susceptible to
carbapenems such as meropenem and imipenem.[13] These
were readily hydrolyzed by the NDM-1 E. coli cells within an
hour or so under our experimental conditions. Aztreonam, an
exception among b-lactams, is not inactivated by metallo-b-
lactamases.[16, 17] Our results are consistent with this observa-
tion: no reduction in the NMR signals of aztreonam is seen in
NDM-1 E. coli cells (Figure 2). It is reported that NDM-1-
producing Klebsiella pneumoniae and E. coli are still suscep-
tible to tigecycline.[16,18] Indeed, our data confirm that
Scheme 1. Hydrolysis of meropenem by the New Delhi Metallo-b-
lactamase subclass 1 (NDM-1). The methyl groups of the substrate
and product shown in green and red, respectively.
Figure 1. 1H NMR spectra of meropenem hydrolysis in the presence of
5 nm purified NDM-1 enzyme (A), E. coli cells (OD600=10.0) without
NDM-1 plasmid (B), and E. coli cells (OD600=2.5) expressing
NDM-1 (C). All samples were prepared in 50 mm sodium phosphate at
pH 7.0 with 10% deuterated water. The hydrolysis of meropenem
(100 mm) at different time points was monitored by focusing on the
1H NMR signals from the nitrogen-attached methyl groups
(Scheme 1). The green and red dotted lines denote the signals of
substrate and product, respectively.
Figure 2. The stability of six antibiotics in the presence of the NDM-1
E. coli cells. The hydrolysis of six antibiotics was monitored through
intensity changes in the methyl-group signals. The starting concentra-
tion of antibiotic was 100 mm and the cells were from the same batch
with an OD600 of 2.5.
Angewandte
Chemie
2131Angew. Chem. Int. Ed. 2014, 53, 2130 –2133  2014 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.angewandte.org
tigecycline is stable in the NDM-1 E. coli cells. Despite the
fact that when using in vitro enzymatic assays, isolated NDM-
1 enzyme shows moderate hydrolysis activity against cepha-
losporins such as cefotaxime and ceftazidime,[17] no detectable
change was observed within an hour when either drug was
incubated with NDM-1 E. coli cells.
In order to protect b-lactam antibiotics from b-lactamase
hydrolysis, a common approach is to combine them with b-
lactamase inhibitors.[12] For instance, ampicillin can be
combined with sulbactam and amoxicillin with clavulanate.
Unfortunately, there are as yet no useful metallo-b-lactamase
(MBL) inhibitors available in clinical application.[12, 13] Since
the first case of NDM-1 was identified in 2008,[19] NDM-1 has
been rapidly disseminated across the continents and has been
detected in a number of Gram-negative pathogens.[13, 18] This
poses a global epidemic threat that could result in a complete
lack of available antibiotics for MBL-aggravated bacterial
infections: “stormy waters ahead”, as Patel and Bonomo
depicted in a recent review on carbapenemases.[13]
l-captopril and ethylenediaminetetraacetic acid (EDTA)
are two known NDM-1 inhibitors.[20, 21] In the crystallographic
structure of NDM-1 in complex with l-captopril, the com-
pound binds to the enzyme and its thiol group interacts with
the two Zn2+ ions at the catalytic site.[22] EDTA, on the other
hand, may simply chelate out the Zn2+ ions that are critical for
the activity of NDM-1. We examined meropenem hydrolysis
by 1H NMR spectroscopy at different inhibitor concentra-
tions. Figure 3 shows that the hydrolysis of meropenem can be
inhibited by adding NDM-1 inhibitors to the cells. EDTA
appears to have a much stronger inhibitory effect on
meropenem hydrolysis than l-captopril. We determined the
fifty percent inhibitory concentrations (IC50 values) of l-
captopril and EDTA to be 175.0 and 1.6 mm, respectively. The
IC50 values of l-captopril and EDTA against the NDM-1
enzyme are reported to be 72 and 0.4 mm, respectively.[20, 21]We
speculate that the bacterial cellular environment, which
contains porins, efflux pumps, and the periplasmic space,
may contribute to the lower inhibitory effect of these
compounds under our whole-cell test conditions. However,
the difference is not substantial.
A unique advantage of studying enzymatic reactions
directly in cells is that other coupled biological components
and functions can be explored as well. In this case, merope-
nem has to pass through the outer membrane barrier ofE. coli
cells through porins to be hydrolyzed by NDM-1 in the
periplasm.[10] Modulation of the open/closed state of porins
should therefore influence the enzymatic reaction in the cell.
Indeed, Figure 4A shows that the rate of meropenem
hydrolysis is dependent upon the concentration of a porin
inhibitor, spermine.[23] By contrast, spermine does not inhibit
the hydrolysis of meropenem by the NDM-1 enzyme in vitro
(Figure 4B). It is likely that spermine reduces the permeation
of meropenem into the periplasm, which limits its access to
NDM-1 and consequently results in a reduction of the rate of
meropenem hydrolysis.
In conclusion, we have shown that 1H NMR spectroscopy
is a simple and powerful method to study bacterial enzyme
functions in their native cellular environment. Although we
have chosen to exemplify the technique with bacterial cells,
we believe the approach has the potential for more general
application to many types of complex biological matrices,
including eukaryotic cell systems. The methodology could
also be applied to challenging proteins, for instance, integral
membrane proteins. The procedures required for the prepa-
ration of membrane proteins for in vitro studies (e.g. deter-
gent solubilization, purification, refolding and reconstitution
in membrane-mimicking lipid bilayers) very often result in
significant loss of activity. By contrast, in our proposed
method, membrane protein function may be assayed directly
in the native membrane milieu and complex sample prepa-
ration is not required. The functional data obtained from
NMRmeasurement is closely related to biological function in
the physiological environment. Our NDM-1 study can be
applied as a target-based whole-cell screen to search for
Figure 3. Inhibition of meropenem hydrolysis in the presence of NDM-
1 E. coli cells by l-captopril (A) and EDTA (B) at various concentra-
tions, and IC50 measurements for l-captopril (C) and EDTA (D). For
each experiment, the NDM-1 E. coli cells (OD600=5.0) were first
incubated with the inhibitor for 10 min and 100 mm meropenem was
subsequently added.
Figure 4. The influence of spermine (a porin inhibitor) on meropenem
hydrolysis by NDM-1 E. coli cells (A) and isolated NDM-1 enzyme (B).
The NDM-1 E. coli cells (OD600=1.0) and 25 nm purified NDM-1
enzyme were first incubated with 0, 1, 5 mm spermine for 10 min.
1H NMR spectra were recorded at 25 8C after the addition of 100 mm
meropenem.
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potent NDM-1 inhibitors. Unlike common phenotypic whole-
cell screening, the NMR approach does not require post-
screen target deconvolution, because the activity of the target
enzyme is monitored through direct spectroscopic observa-
tion of substrate/product turnover. Moreover, compound
access to the target within the cell is implicitly accounted for
in the screening. This novel screening approach is currently
under development for other applications.
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